Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.

ABSTRACT:

Importance

Elevated fibroblast growth factor 23 (FGF-23) concentrations are associated with myocardial fibrosis and renin-angiotensin system upregulation, potentially providing prognostic information distinct from standard cardiovascular (CV) biomarkers.

Objective

To evaluate the association of FGF-23 with recurrent CV events in patients after an acute coronary syndrome (ACS).

Design, setting, and participants

C-terminal FGF-23 was measured in plasma samples using an established enzyme-linked immunosorbent assay system for 4947 patients within 30 days of ACS (median, 14 days) and with 1 additional CV risk factor in the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial of the lipoprotein-associated phospholipase A2

SUBMITTER: Bergmark BA 

PROVIDER: S-EPMC6128514 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature